EvaluatePharma Vision

The first single view of the risk and reward of the R&D landscape

EvaluatePharma Vision builds on EvaluatePharma to combine proprietary R&D analytics, an NPV valuation platform, a calendar of market catalysts and our market leading consensus forecasts. 

Our R&D analytics include success rates, predictive timelines, clinical trial outcomes and a unique view of R&D costs to give you the first single view of the risk and reward of the R&D landscape.  

Full transparency and consistent methodologies on all analytics give you the confidence to make investment decisions quickly, with less risk and lower cost.

Contact Us Download Brochure
Pills in cubes

More speed. Less risk. Lower cost.

  • Identify risk and evaluate potential assets earlier in the screening process. 
  • Present a comprehensive competitive landscape for faster, more effective decision-making. 
  • Benchmark your company’s R&D performance against your competitors. 
  • Evaluate and prioritise your R&D portfolio with unbiased risk/return metrics.

Success Rates

The most comprehensive view of R&D success rates available with analysis of over 19,000 phase transitions from 2000 onwards. Fully transparent
probability of technical and regulatory success (PTRS) benchmarks at an industry level, and by indication, mechanism of action and technology.

Pills in a cube
Fragmented World

R&D Costs

The industry’s first comprehensive clinical trial costing model, with over 50,000 trials costed: view costs at a trial, drug or indication level. Fully
transparent R&D cost benchmarks by indication and phase.

Timelines

Our consistent proprietary methodology helps to predict US and EU approval dates for all NMEs in clinical development, even early-stage assets not covered by brokers. Includes time-in-phase benchmarks for 840+ indications, with a fully transparent audit of how these are calculated for each phase. 

Past Present Future
Pills in a cube

Outcomes

Aggregated and standardised trial outcomes for indications and products updated daily. Information from multiple sources, combined to produce proprietary endpoint analysis focused on the four indication-specific endpoints most likely to lead to regulatory approval.

Clinical Trials

Track and analyse clinical trials in the commercial context with ClinicalTrials.gov, EudraCT and a Japan clinical trials data source aggregated, standardised and integrated.

Calendar of Events

Identify and track future critical events and market catalysts for product lifecycles. Track key events, including Phase II and III trial initiation, completion and results, financial results, product filings and approvals, and expected generic competition.

Interactive NPV Analyzer

Access NPV discounted cash flow models for over 4,500 products. Interactive, fully transparent models let you edit key assumptions – annual and peak sales, patent expiry date, cost of capital and tax rate – to create a custom model.

We know Evaluate has done the work and looked at the data, and we trust the answers they give us. Our management is happy when they see Evaluate's name.

Anthony M, Senior Director, Competitive Intelligence & Prospection, Novartis

Evaluate's consensus forecasts commentary highlights the main drivers of a forecast - knowledge that's critical when I am working with brand teams or the C-suite executives.

Marketing Science Manager, Genentech